Trial Profile
A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms GATA
- 16 Sep 2022 Status changed from active, no longer recruiting to completed.
- 06 Dec 2021 Planned End Date changed from 1 Nov 2021 to 22 Aug 2022.
- 17 Jun 2021 Results from a cohort of patients with indolent non-hodgkins lymphoma (n=78) presented at the 26th Congress of the European Haematology Association